Events & Ideas

Our Work

OTC Products

National Geographic Recognizes OTC Oral Contraceptive Opill as a Key Medical Breakthrough in 2024

https://www.nationalgeographic.com/science/article/top-medical-breakthroughs-2024 “A birth control pill without a prescription” “This year the first-ever birth control pill became available in the United States without a prescription. The U.S. Food and Drug Administration (FDA) had approved the daily oral medication, Opill, last year and it is now available to anyone regardless of age, insurance coverage, or whether they’ve… Read More

OTC Products

Pinney Associates is honored to have been a part of the teams who worked tirelessly to achieve FDA approval of over-the-counter Opill, the first oral contraceptive to be made available without a prescription in the US (approved July 13, 2023). Popular Science’s 50 greatest innovations of 2023

OTC Products

2023 CHPA’s Regulatory, Scientific & Quality Conference (RSQ)

September 19-20, 2023 | Bethesda, MD Lucy Owen and Christine Sweeney will be attending. VIEW CONFERENCE

OTC Products

A Novel 3 mg Naloxone Nasal Spray for the Over-the-Counter Market

Ashworth J, Davis VG, Mannion R, Hufford M To be presented at the 85th CPDD Annual Scientific Meeting, Poster Session 2, June 19, 2023.

OTC Products, Dietary Ingredients & Supplements

2023 CHPA Annual Self-Care Leadership Summit

March 19-21, 2023 | Orlando, FL Lucy Owen will be attending VIEW CONFERENCE WEBSITE

OTC Products

Considerations for the Future of Rx-to-OTC Switches

Moderator David Spangler, J.D., Senior Vice President, Legal, Government Affairs & Policy, CHPA Speakers Bernie Simone, Vice President of Client Strategy and Rx-to-OTC Switch, Pinney Associates Clark Richardson, MPH, President & CEO, PEGUS Research, Inc. Mary Alice Lawless, Founder and Chief Client Officer, Biograph Inc. Francis E. Becker, M.D., FACP, Director, Division of Nonprescription Drugs… Read More

OTC Products

Complexities of planning, developing, and validating a switch opportunity via a regulatory pathway

Bernie Simone, Vice President of Client Strategy and Rx-to-OTC Switch, Pinney Associates Presented at Rx-to-OTC Switch Symposium, Dynamic Global Events, March 15-16, 2021

OTC Products

Rx to OTC Switch (Part 2 of 2): Planning for Commercial Success

Christine Sweeney, PhD, MPH, Director, Issues Management, Pinney Associates George Quesnelle, Senior Strategic Advisor, OTC Commercialization and Optimization, Pinney Associates Presented February 22, 2018 Visit Webinar Website